%0 Journal Article
%A Jungwirth, Gerhard
%A Cao, Junguo
%A Pan, Yimin
%A Warta, Rolf
%A Lotsch, Catharina
%A Moustafa, Mahmoud
%A Knoll, Maximilian
%A Yu, Tao
%A Braun, Viktor
%A Jassowicz, Lena
%A Trong, Philip Dao
%A Wang, Zhenlin
%A Younsi, Alexander
%A Scherer, Moritz
%A Bendszus, Martin
%A Krieg, Sandro M
%A von Deimling, Andreas
%A Debus, Juergen
%A Abdollahi, Amir
%A Unterberg, Andreas
%A Sahm, Felix
%A Herold-Mende, Christel
%T Drug screening on tumor organoids exposes therapeutic vulnerabilities of meningiomas to HDAC1/2i panobinostat.
%J Science translational medicine
%V 18
%N 839
%@ 1946-6234
%C Washington, DC
%I AAAS
%M DKFZ-2026-00519
%P eaea3115
%D 2026
%X Managing aggressive meningiomas remains challenging because of limited treatment options besides surgical tumor removal and radiotherapy. To increase the repertoire of promising therapies for aggressive meningiomas, we established a multistep drug screening workflow, focusing on targetable genes obtained from transcriptome data of highly aggressive grade 3 meningiomas. In vitro screening of 107 targeted drugs identified nine effective inhibitors. To study these drugs in a more natural environment, we established a standardized patient-derived tumor organoid (TO) model preserving accurately the original tissue's genotype and phenotype. Individual drug responses were assessed in TOs from 60 meningioma cases characterized at the molecular level. In particular, the US Food and Drug Administration-approved epigenetic drug panobinostat demonstrated high antimeningioma efficacy in 70
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41779868
%R 10.1126/scitranslmed.aea3115
%U https://inrepo02.dkfz.de/record/310296